Sensitized renal transplant recipients: Current protocols and future directions

Nature Reviews Nephrology

Volumn 6, Issue 5, 2010, Pages 297-306

  Gloor, James ^a   Stegall, Mark D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5 INHIBITOR; HLA ANTIBODY; IMMUNOGLOBULIN; PROTEASOME INHIBITOR;

CLINICAL TRIAL; DESENSITIZATION; DRUG MEGADOSE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; GLOMERULOPATHY; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOLOGY; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BLOOD FLOW; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROVASCULATURE; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION;

ADSORPTION; ANTIBODY SPECIFICITY; COMPLEMENT C5; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; PLASMA EXCHANGE; PROTEASOME ENDOPEPTIDASE COMPLEX; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY;

EID: 77951879759     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.34     Document Type: Review

References (112)

1. Annual Report 1998-2007 HHS/HRSA/HSB/ DOT (OPTN/SRTR, 2008).
2. Moore, S. B., Sterioff, S., Pierides, A. M., Watts, S. K. & Ruud, C. M. Transfusion-induced alloimmunization in patients awaiting renal allografts. Vox Sang. 47, 354-361 (1984).
3. Montgomery, R. A. et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70, 887-895 (2000).
4. Schweitzer, E. J. et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 70, 1531-1536 (2000).
5. Glotz, D. et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IvIg). Am. J. Transplant. 2, 758-760 (2002).
6. Jordan, S. C. et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76, 631-636 (2003).
7. Gloor, J. M. et al. Overcoming a positive crossmatch in living donor kidney transplantation. Am. J. Transplant. 3, 1017-1023 (2003).
8. Koch, C. A., Khalpey, Z. I. & Platt, J. L. Accommodation: preventing injury in transplantation and disease. J. Immunol. 172, 5143-5148 (2004).
9. Salama, A. D. et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am. J. Transplant. 1, 260-269 (2001).
10. Thielke, J. J. et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 87, 268-273 (2009).
11. Magee, C. C. et al. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 86, 96-103 (2008).
12. Vo, A. A. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242-251 (2008).
13. Porter, K. A. The effects of antibodies on human renal allografts. Transplant. Proc. 8, 189-192 (1976).
14. Kissmeyer-Nielsen, F., Olsen, S., Petersen, V. F. & Fjeldborg, O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 2, 662-665 (1966).
15. Patel, R. & Terasaki, P. I. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 280, 735-739 (1969).
16. Ray, J. G. (ed.) NIH lymphocyte microlymphocytotoxicity technique. US DHeW Publication No [NIH] 39, 80-545 (1979).
17. Zachary, A. A., Klingman, L., Thorne, N., Smerglia, A. R. & Teresi, G. A. variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity. Transplantation 60, 498-503 (1995).
18. Cho, W. Y. & Cecka, J. M. in Clinical Transplants 2001 (ed. Cecka, J. M.) 237-246 (Los Angeles, CA, 2001).
19. Bray, R. A. Flow cytometry in the transplant laboratory. Ann. NY Acad. Sci. 677, 138-151 (1993).
20. Ten Hoor, G. M., Coopmans, M. & Allebes, W. A. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival. Transplantation 56, 298-304 (1993).
21. Chapman, J. R., Taylor, C. J., Ting, A. & Morris, P. M. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 42, 608-613 (1986).
22. Ayoub, G., Park, M. S., Terasaki, P. I., Iwaki, Y. & Opelz, G. B cell antibodies and crossmatching. Transplantation 29, 227-229 (1980).
23. Bryan, C. F. et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 66, 1827-1832 (1998).
24. Christiaans, M. H. et al. No advantage of flow cytometry crossmatch over complementdependent cytotoxicity in immunologically welldocumented renal allograft recipients. Transplantation 62, 1341-1347 (1996).
25. Ting, A. & Morris, P. J. Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies. Lancet 2, 1095-1097 (1977).
26. Taylor, C. J., Chapman, J. R., Ting, A. & Morris, P. J. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation: relationship to primary and regraft outcome. Transplantation 48, 953-958 (1989).
27. Pei, R., Lee, J.-H., Shih, N.-J., Chen, M. & Terasaki, P. I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75, 43-49 (2003).
28. Pei, R., Lee, J.-H., Chen, T., Rojo, S. & Terasaki, P. I. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum. Immunol. 60, 1293-1302 (1999).
29. Zachary, A. A., Lucas, D. P., Detrick, B. & Leffell, M. S. Naturally occurring interference in LuminexTM assays for HLA-specific antibodies: characteristics and resolution. Hum. Immunol. 70, 496-501 (2009).
30. El-Awar, N., Lee, J. & Terasaki, P. I. HLA antibody identification with single antigen beads compared to conventional methods. Hum. Immunol. 66, 989-997 (2005).
31. Colombo, M. B. et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin. Cytom. 72, 465-471 (2007).
32. Gibney, E. M. et al. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol. Dial. Transplant. 21, 2625-2629 (2006).
33. Amico, P. et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single antigen flow-beads. Transplantation 87, 1681-1688 (2009).
34. Mizutani, K. et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am. J. Transplant. 7, 1027-1031 (2007).
35. Gloor, J. M. et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am. J. Transplant. 10, 582-589 (2010).
36. Campos, E. F. et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am. J. Transplant. 6, 2316-2320 (2006).
37. Langan, L. L. et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am. J. Transplant. 7, 847-856 (2007).
38. Pollinger, H. S. et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am. J. Transplant. 7, 857-863 (2007).
39. Gloor, J. M. et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am. J. Transplant. 7, 2124-2132 (2007).
40. Scornik, J. C. et al. Hyperacute and acute kidney graft rejection due to antibodies against B cells. Transplantation 54, 61-64 (1992).
41. Berg, B. & Möller, E. Immediate rejection of a HLA-A, B compatible HLA-DR incompatible kidney with a positive donor-recipient B-cell crossmatch. Scand. J. Urol. Nephrol. 54, 36 (1980).
42. Claas, F. H., Witvliet, M. D., Duquesnoy, R., Persijn, G. G. & Doxiadis, I. I. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 78, 190-193 (2004).
43. Bray, R. A. et al. Transplanting the highly sensitized patient: the emory algorithm. Am. J. Transplant. 6, 2307-2315 (2006).
44. Zangwill, S. D. et al. The virtual crossmatch-a screening tool for sensitized pediatric heart transplant recipients. Pediatr. Transplant. 10, 38-41 (2006).
45. Appel, J. Z. et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 81, 1049-1057 (2006).
46. Stegall, M. D., Dean, P. G. & Gloor, J. M. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am. J. Transplant. 9, 998-1005 (2009).
47. Racusen, L. C. et al. Antibody-mediated rejection criteria- an addition to the Banff '97 classification of renal allograft rejection. Am. J. Transplant. 3, 708-714 (2003).
48. Crespo, M. et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology, and clinical characteristics. Transplantation 71, 652-658 (2001).
49. Pescovitz, M. D. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Clin. Transplant. 20, 48-54 (2006).
50. Akalin, E. et al. The addition of plasmapheresis decreases the incidence of acute antibodymediated rejection in sensitized patients with strong donor-specific antibodies. Clin. J. Am. Soc. Nephrol. 3, 1160-1167 (2008).
51. Akalin, E. et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch positive patients. Transplantation 76, 1444-1447 (2003).
52. Jordan, S. C. et al. evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: a report of the NIH IG02 trial. J. Am. Soc. Nephrol. 15, 3256-3262 (2004).
53. Tyan, D., Li, V. A., Czer, L., Trento, A. & Jordan, S. C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 57, 553-562 (1994).
54. Dwyer, J. M. Manipulating the immune system with immune globulin. N. Engl. J. Med. 326, 107-116 (1992).
55. Jordan, S. C. & Toyoda, M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin. Exp. Immunol. 97 (Suppl. 1), 31-38 (1994).
56. Tankersley, D. L., Preston, M. S. & Finlayson, J. S. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol. Immunol. 25, 41-48 (1988).
57. Jordan, S. C., Cunningham-Rundles, C. & Mcewan, R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am. J. Transplant. 3, 653-664 (2003).
58. Jordan, S. C., Tyan, D., Czer, L. & Toyoda, M. Immunomodulatory actions of intravenous immunoglobulin (IvIG): potential applications in solid organ transplant recipients. Pediatr. Transplant. 2, 92-105 (1998).
59. Rossi, F., Dietrich, G. & Kazatchkine, M. D. Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. Res. Immunol. 140, 19-31 (1989).
60. Magee, J. C. et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J. Clin. Invest. 96, 2404-2412 (1995).
61. Zachary, A. A. et al. 14th international HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens 69 (Suppl. 1), 160-173 (2007).
62. Jordan, S. C., Toyoda, M. & Vo, A. A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88, 1-6 (2009).
63. Anthony, R. M., Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IvIG. Proc. Natl Acad. Sci. USA 105, 19571-19578 (2008).
64. Toyoda, M., Pao, A., Petrosian, A. & Jordan, S. C. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am. J. Transplant. 3, 156-166 (2003).
65. Lefaucheur, C. et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am. J. Transplant. 8, 324-331 (2008).
66. Pascual, M. et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66, 1460-1464 (1998).
67. Haririan, A. et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am. J. Transplant. 9, 536-542 (2009).
68. Elkayam, O. et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann. Rheum. Dis. 59, 77-80 (2000).
69. Go, R. S. & Call, T. G. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin. Proc. 75, 83-85 (2000).
70. Stegall, M. D., Gloor, J. M., Winters, J. L., Moore, S. B. & DeGoey, S. A comparison of plasmapheresis versus high dose IvIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 6, 346-351 (2006).
71. Kupin, W. L. et al. Removal of lymphcytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation 51, 324-329 (1991).
72. Palmer, A. et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1, 10-12 (1989).
73. Gloor, J. M. et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am. J. Transplant. 6, 1841-1847 (2006).
74. Gloor, J., Cosio, F., Lager, D. J. & Stegall, M. D. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am. J. Transplant. 8, 1367-1373 (2008).
75. Lajoie, G. Antibody-mediated rejection of human renal allografts: an electron microscopic study of peritubular capillaries. Ultrastruct. Pathol. 21, 235-242 (1997).
76. Lipták, P. et al. Peritubular capillary damage in acute humoral rejection: an ultrastructural study on human renal allografts. Am. J. Transplant. 5, 2870-2876 (2005).
77. Wavamunno, M. D. et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am. J. Transplant. 7, 2757-2768 (2007).
78. Monga, G., Mazzuco, G., Novara, R. & Reale, L. Intertubular capillary changes in kidney allografts: An ultrastructural study in patients with transplant glomerulopathy. Ultrastruct. Pathol. 14, 201-209 (1990).
79. Racusen, L. C. et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 55, 713-723 (1999).
80. Solez, K. et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am. J. Transplant. 7, 518-526 (2007).
81. Bian, H., Harris, P. E. & Reed, E. F. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int. Immunol. 10, 1315-1323 (1998).
82. Jindra, P. T., Jin, Y.-P., Rozengurt, E. & Reed, E. F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J. Immunol. 180, 2357-2366 (2008).
83. Atz, M. E. & Reed, E. F. Role of anti-MHC class I antibody in facilitating transplant accommodation. Crit. Rev. Immunol. 28, 485-511 (2008).
84. Haas, M. et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am. J. Transplant. 7, 576-585 (2007).
85. Kraus, E. S. et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am. J. Transplant. 9, 1826-1834 (2009).
86. Lerut, E., Naesens, M., Kuypers, D. R., Vanrenterghem, Y. & Van Damme, B. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 83, 1416-1422 (2007).
87. Mauiyyedi, S. et al. Acute humoral rejection in kidney transplantation: II. morphology, immunopathology, and pathologic classification. J. Am. Soc. Nephrol. 13, 779-787 (2002).
88. Trpkov, K. et al. Pathologic features of acute renal allograft rejection associated with donorspecific antibody. Analysis using the Banff Grading Schema. Transplantation 61, 1586-1592 (1996).
89. Feucht, H. E. et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 43, 1333-1338 (1993).
90. Takemoto, S. K. et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant. 4, 1033-1041 (2004).
91. Pretagostini, R. et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J. 42, M645-M648 (1996).
92. Böhmig, G. A. et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am. J. Transplant. 7, 117-121 (2007).
93. Jordan, S. C., Vo, A. A., Toyoda, M., Tyan, D. & Nast, C. C. Post-transplant therapy with highdose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr. Transplant. 9, 155-161 (2005).
94. Shah, A. et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77, 1399-1405 (2004).
95. Becker, Y. T., Becker, B. N., Pirsch, J. D. & Sollinger, H. W. Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. 4, 996-1001 (2004).
96. Alausa, M. et al. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin. Transplant. 19, 137-140 (2005).
97. Faguer, S. et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83, 1277-1280 (2007).
98. Kaplan, B. et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 83, 99-100 (2007).
99. Locke, J. E. et al. The utility of splenectomy as a rescue treatment for severe acute antibody mediated rejection. Am. J. Transplant. 7, 842-846 (2007).
100. Ramos, E. J. et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am. J. Transplant. 7, 402-407 (2007).
101. Rother, R. P. et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am. J. Transplant. 8, 1129-1142 (2008).
102. Locke, J. E. et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant. 9, 231-235 (2009).
103. Burns, J. M. et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am. J. Transplant. 8, 2684-2694 (2008).
104. Stegall, M. D. et al. Prevention of acute humoral rejection with C5 inhibition. Am. J. Transplant. 9 (Suppl. 2), 241 (2009).
105. Cornell, L. D., Burns, J. M. & Stegall, M. D. Prevention of endothelial cell activation with C5 inhibition in positive crossmatch kidney transplants. Am. J. Transplant. 9 (Suppl. 2), 304 (2009).
106. Perry, D. K. et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IvIG and rATG. Am. J. Transplant. 8, 133-143 (2008).
107. Wu, J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am. J. Transplant. 2, 904-912 (2002).
108. Rajkumar, S. V., Richardson, P. G., Hideshima, T. & Anderson, K. C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630-639 (2005).
109. Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
110. Everly, M. J. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86, 1754-1761 (2008).
111. Perry, D. K. et al. Proteosome inhibition causes apoptosis of normal human plasma cells preventing antibody production. Am. J. Transplant. 9, 201-209 (2009).
112. Diwan, T. S. et al. effect of proteasome inhibition on alloantibody secreting cells in vivo. Am. J. Transplant. 9 (Suppl. 2), 241 (2009).